Chronobiology and chronotherapy of allergic rhinitis and bronchial asthma

Advanced Drug Delivery Reviews

Volumn 59, Issue 9-10, 2007, Pages 852-882

  Smolensky, Michael H ^a   Lemmer, Bjoern ^b   Reinberg, Alain E ^c  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

Author keywords

Allergic rhinitis; Bronchial asthma; Chronopharmacology; Chronotherapy; Circadian rhythm; Glucocorticosteroids; H1 antagonists; Luekotriene antagonists; Theophylline; 2 agonists

Indexed keywords

ANTIGENS; DRUG DELIVERY; MICROBIOLOGY; PATIENT TREATMENT; PHARMACOKINETICS; TISSUE;

BRONCHIAL ASTHMA (BA); CHRONOPHARMACOLOGY; CHRONOTHERAPY; GLUCOCORTICOSTEROIDS; MUCUS HYPERSECRETION;

DISEASES;

ATROPINE; BAMBUTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRICANYL DEPOT; BRONCHODILATING AGENT; CHLORPHENIRAMINE MALEATE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CICLESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; DESLORATADINE; DUTIMELAN; FLUTICASONE PROPIONATE; FORMOTEROL; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; IPRATROPIUM BROMIDE; KRONOFED A; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEQUITAZINE; METHYLPREDNISOLONE; MOMETASONE FUROATE; NEDOCROMIL SODIUM; PSEUDOEPHEDRINE; SALBUTAMOL; SALBUTAMOL SULFATE; TERBUTALINE; TERFENADINE; THEOPHYLLINE; TRIAMCINOLONE ACETONIDE; TULOBUTEROL; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; AREA UNDER THE CURVE; ASTHMA; BRONCHUS HYPERREACTIVITY; CHRONOBIOLOGY; CHRONOPHARMACOLOGY; CHRONOTHERAPY; CIRCADIAN RHYTHM; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LOW DRUG DOSE; NEUROENDOCRINE SYSTEM; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROVOCATION TEST; RESPIRATORY TRACT INFLAMMATION; REVIEW; SLEEP; SUSTAINED RELEASE FORMULATION; TOXICOLOGY; VOLUNTEER;

EID: 35148824741     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.08.016     Document Type: Review

References (266)

1. Trousseau A. Clinique medicale de L'Hotel dieu Paris vol. 2 (1865), Bailliere, Paris 373
2. Nicholson P.A., and Bogie W. Diurnal variation in the symptoms of hay fever: implications for pharmaceutical development. Curr. Med. Res. Opin. 1 (1973) 395-401
3. Binder E., Holopainen E., Malmberg H., and Salo O. Anamnestic data in allergic rhinitis. Allergy 37 (1982) 389-396
4. Reinberg A., Gervais P., Lévi F., Smolensky M.H., Del Cerro L., and Ugolini C. Circadian and circannual rhythms of allergic rhinitis: an epidemiologic study involving chronobiologic methods. J. Allergy Clin. Immunol. 81 (1988) 51-62
5. Craig T.J., McCann J.L., Gurevich F., and Davies M.J. The correlation between allergic rhinitis and sleep disturbance. J. Allergy Clin. Immunol. 114 5, Suppl.1 (2004) S139-S145
6. Stuck B.A., Czajkowshi J., Hagner A.E., Klimek L., Verse T., Hörmann K., and Maurer T.J. Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: a controlled clinical trial. J. Allergy Clin. Immunol. 113 (2004) 663-668
7. Vuurman E.F., van Veggel L.M., Uiterwijk M.M., Leutner D., and O'Hanlon J.F. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann. Allergy, Asthma, & Immun. 71 (1993) 121-126
8. Kessler R.C., Almedia D.M., Berglund P., and Stang P. Pollen and mold exposure impairs work performance of employees with allergic rhinitis. Ann. Allergy, Asthma, & Immun. 87 (2001) 289-295
9. Tanner L.A., Reilly M., Meltzer E.O., Bradford J.E., and Mason J. Effect of fexofenadine HCL on quality of life and work, classroom, and daily activity impairment in patients with seasonal allergic rhinitis. Ann. J. Managed Care 5 Suppl 4 (1999) S235-S247
10. Ferguson B.J. Influences of allergic rhinitis on sleep. Otolaryngol. Head Neck Surg. 130 (2004) 617-629
11. Storms W.W. Minimal persistent inflammation, an emerging concept in the nature and treatment of allergic rhinitis: the possible role of leukotrienes. Ann. Allergy, Asthma, & Immun. 91 (2003) 131-140
12. Storms W.W. Pharmacologic approaches to daytime and nighttime symptoms of allergic rhinitis. J. Allergy Clin. Immunol. 114 5 Suppl. 1 (2004) S146-S153
13. Rosenwasser L. New insights into the pathophysiology of allergic rhinitis. Allergy Asthma Proc. 28 (2007) 10-15
14. Hansen I., Klimek L., Msges R., and Hörmann K. Mediators of inflammation in the early and late phase of allergic rhinitis. Curr. Opin. Allergy Clin. Immunol. 4 (2004) 159-163
15. Van Bever H.P. Recent advances in the pathogenesis of atopic dermatitis. Eur. J. Pediatr. 151 (1992) 870-873
16. Massey W.A. Pathogenesis and pharmacologic modulation of the cutaneous late-phase reaction. Ann. Allergy 71 (1993) 578-584
17. Barnes P.J., Fitzgerald G., Brown M., and Dollery C. Nocturnal asthma and changes in circulating epinephrine, histamine, and cortisol. N. Engl. J. Med. 303 (1980) 263-267
18. Aoyagi M., Watanabe H., Sekine K., Nishimuta T., Konno A., Shimojo N., and Kohno Y. Circadian variations in nasal reactivity in children with allergic rhinitis: correlation with the activity of eosinophils and basophilic cells. Int. Arch. Allergy Immunol. 120 Suppl 1 (1999) 95-99
19. Rundcrantz H. Postural variations of nasal patency. Acta Otolaryngol. 68 (1969) 435-443
20. Young T., Finn L., and Kim H. Nasal obstruction as a risk factor for sleep-disordered breathing. J. Allergy Clin. Immunol. 99 (1997) S757-S762 (Suppl)
21. McColley S.A., Carroll J.L., Curtis S., Loughlin G.M., and Sampson H.A. High prevalence of allergic sensitization in children with habitual snoring and obstructive sleep apnea. Chest 111 (1997) 170-173
22. Lavie P., Gertner R., Zomer J., and Podoshin L. Breathing disorders in sleep associated with "microarousals" in patients with allergic rhinitis. Acta Otolaryngol. 92 (1981) 529-533
23. Reinberg A., and Sidi E. Circadian changes in the inhibitory effects of an antihistaminic drug in man. J. Invest. Dermatol. 46 (1966) 415-419
24. Reinberg A., Lévi F., Guillet P., Burke J.T., and Nicolai A. Chronopharmacologic study of antihistamines with special reference to terfenadine. Eur. J. Clin. Pharmacol. 14 (1978) 245-252
25. Reinberg A., Lévi F., Fourtillan J.P., Pfeiffer C., Bicakova-Rocher A., and Nicolai A. Antihistamine and other effects of 5 mg mequitazine vary between morning and evening acute administration. Annu. Rev. Chronopharmacol. 1 (1984) 57-60
26. 1-antihistamines. In: Lemmer B.J. (Ed). Chronopharmacology: Cellular and Biochemical Interactions (1989), Marcel Dekker, New York 115-135
27. Reinberg A., Sidi E., and Ghata J. Circadian rhythms of human skin to histamine or allergen and the adrenal cycle. J. Allergy Clin. Immunol. 36 (1965) 273-283
28. Reinberg A., Zagulla-Mally Z., Ghata J., and Halberg F. Circadian reactivity rhythms of human skin to house dust, penicillin and histamine. J. Allergy Clin. Immunol. 44 (1969) 292-306
29. Lee R.E., Smolensky M.H., Leach C., and McGovern J.P. Circadian rhythms in cutaneous sensitivity to histamine and selected antigens including phase relationship to urinary cortisol excretion. Ann. Allergy 38 (1977) 231-236
30. McGovern J.P., Smolensky M.H., and Reinberg A. Circadian and circamensual rhythmicity in cutaneous reactivity to histamine and allergenic extracts. In: McGovern J.P., Smolensky M.H., and Reinberg A. (Eds). Chronobiology in Allergy and Immunology (1977), Charles C. Thomas, Springfield, Il. 79-116
31. Reinberg A., Gervais P., Ugolini C., Del Cerrro L., and Bicakova-Rocher A. A multicentric chronotherapeutic study of mequitazine in allergic rhinitis. Annu. Rev. Chronopharmacol. 3 (1985) 441-444
32. Haye R., Høye K., Berg O., Frønes S., and Odegård S.T. Morning versus evening dosing of desloratadine in seasonal allergic rhinitis: a randomized controlled study. Clin. Mol. Allergy 3 (2005) 3 (abstract)
33. Geha R.S., and Meltzer E.O. Desloratadine: a new, nonsedating, oral antihistamine. J. Allergy Clin. Immunol. 107 (2001) 751-762
34. Caelius A. De Morbis Acutis and Chronicis, J.C. Amman, recensuit, emaculavit, notulasque adjecit, Editio nova (1722), Wetsten, Amsterdam
35. Adams F. (Ed. and Trans.). The Extant Works of Aretaeus (Printed for the Syndenham Society) (1856), The Cappadocian, London
36. Wirsung Ch. Arzney-Buch (1568), Johannem Mayer, Heidelberg
37. Castello P.V. Exercitationes Medicinales Ad Omnes Thoracis Affectus, Decem Tractatibus Absoluta, Raymon Colomerius, Toulouse (1616)
38. Floyer J. A Treatise of the Asthma (1698), R. Wilkins & W. Innis, London
39. In: Martin R.J. (Ed). Nocturnal Asthma. Mechanisms and Treatment (1993), Futura Publishing Co. Inc., Mount Kisco, NY 394 pp.
40. Smolensky M.H., and Halberg F. Circadian rhythm in airway patency and lung volumes. In: McGovern J.P., Smolensky M.H., and Reinberg A. (Eds). Chronobiology in Allergy and Immunology (1977), C.C. Thomas, Springfield, Il. 117-138
41. Hetzel M.R., and Clark T.J.H. Comparison of normal and asthmatic circadian rhythms in peak expiratory flow rate. Thorax 35 (1980) 732-738
42. Dethlefsen U., and Repges R. Ein neues therapieprinzip bei nachtlichem asthma. Med. Klin. 80 (1985) 44-47
43. Turner-Warwick M. Epidemiology of nocturnal asthma. Am. J. Med. 85 suppl 1B (1988) 6-8
44. Smith E. Recherches experimentales sur la respiration. J. Physiol. l'Homme Anim. 3 (1860) 506-521
45. Smolensky M.H., Barnes P.J., Reinberg A., and McGovern J.P. Chronobiology and asthma. I. Day-night differences in bronchial patency and dyspnea and circadian rhythm dependencies. J. Asthma 23 (1986) 321-343
46. Storms W.W., Bodman S.F., Nathan R.A., and Byer P. Nocturnal asthma symptoms may be more prevalent than we think. J. Asthma 31 (1994) 313-318
47. Hetzel M.R., Clark T.J.H., and Branthwaite M.A. Asthma: analysis of sudden deaths and ventilatory arrest in hospital. Br. Med. J. 1 (1977) 808-811
48. Cochrane G.M., and Clark T.J.H. A survey of asthma mortality in patients between 35 and 65 years in the greater London hospitals in 1971. Thorax 30 (1975) 300-315
49. Anonymous. Death from asthma in two regions of England. Br. Med. J. 285 (1982) 1251-1255
50. Bateman J.R.M., and Clark S.W. Sudden death in asthma. Thorax 34 (1979) 40-44
51. Douglas N.J. Asthma at night. Clin. Chest Med. 6 (1985) 663-674
52. Newman Taylor A.N., Davies R.J., Hendrick D.J., and Pepys J. Recurrent nocturnal asthmatic reactions to bronchial provocation tests. Clin. Allergy 9 (1979) 213-219
53. Barnes P.J., and Pauwels R.A. Theophylline in the management of asthma: time for reappraisal?. Eur. Respir. J. 7 (1994) 579-591
54. Cockcroft D.W., Hoeppner V.H., and Werner G.D. Recurrent nocturnal asthma after bronchoprovacation with western red cedar sawdust: association with acute increase in non-allergic bronchial responsiveness. Clin. Allergy 14 (1984) 61-68
55. Davies K.J., Green M., and Schofield N.M. Recurrent nocturnal asthma after exposure to grain dust. Am. Rev. Dis. 114 (1976) 1011-1019
56. Harkness J.A.L., Richter M.B., Pamayi G.S., Van DePete K., Unger K., Pownall K., and Geddawi M. Circadian variation in disease activity in rheumatoid arthritis. Br. Med. J. 284 (1982) 551-554
57. Labrecque G., and Reinberg A. Chronopharmacology of nonsteroidal anti-inflammatory drugs. In: Lemmer B. (Ed). Chronopharmacology. Cellular and Biochemical Interactions (1989), Marcel Dekker, NY 545-579
58. Smolensky M.H., Reinberg A., and Labrecque G. Twenty-four hour pattern in symptom intensity of viral and allergic rhinitis: treatment implication. J. Allergy Clin. Immunol. 95 (1995) 1084-1096
59. Martin R.J.L., Cicutto L.C., Smith H.R., Ballard R.D., and Szefler S.J. Airways inflammation in nocturnal asthma. Am. Rev. Respir. Dis. 143 (1991) 351-357
60. Kraft M., Djukanovics R., Wilson S., Holgate S.T., and Martin R.J. Alveolar tissue inflammation in asthma. Am. J. Respir. Crit. Care Med. 154 (1996) 1505-1510
61. Kraft M., Martin R.J., Wilson S., Djukanovic R., and Holgate S.T. Lymphocytes and eosinophil influx into alveolar tissue in nocturnal asthma. Am. J. Respir. Crit. Care Med. 159 (1999) 228-234
62. Jarjour N.N., Calhoun W.J., and Busse W.W. Enhanced metabolism of oxygen radicals in nocturnal asthma. Am. Rev. Respir. Dis. 146 (1992) 905-911
63. Calhoun W.J., Bates M.E., Schrader L., Sedgwick J.B., and Busse W.W. Characteristics of peripheral blood eosinophils in patients with nocturnal asthma. Am. Rev. Respir. Dis. 145 (1992) 577-581
64. Thomas A., Petro W., and Konietzko N. Untersuchungen zur zirkadianen Rhythmik der Schlagfrequenz menschlicher Nasenzilien bei Lungengesunden und Patienten mit chronisch obstruktiver Lungenerkrankung. Einschliesslich der adrenergen Stimulation durch Terbutalin. Pneumologie 47 (1993) 526-530
65. Bonnet R., Jorres R., Heitmann U., and Mangnussen H. Circadian rhythm in airway responsiveness and airway tone in patients with mild asthma. J. Appl. Physiol. 71 (1991) 1598-1605
66. DeVries K.J.T., Goei H., Booy-Noord H., and Orie N.G.M. Changes during 24 hours in lung function and histamine hyperreactivity of the bronchial tree in asthmatic and bronchitic patients. Arch. Allergy Appl. Immunol. 20 (1962) 93-101
67. Gervais P., Reinberg A., Gervais C., and Smolensky M.H. Twenty-four-hour rhythm in the bronchial hyperreactivity to house dust in asthmatics. J. Allergy Clin. Immunol. 59 (1977) 207-213
68. Reinberg A., Gervais P., Morin P., and Abulker C. Rhythme circadian humain du seuil de la reponse bronchique a l'acétylcholine. C.R. Acad. Sci. 272 (1971) 1879-1881
69. Jarjour N.N. Circadian variation in allergen and non-specific bronchial responsiveness in asthma. Chronobiol. Int. 16 (1999) 631-639
70. Reinberg A., Ghata J., and Sidi E. Nocturnal asthma attacks: their relationship to the circadian adrenal cycle. J. Allergy 34 (1963) 323-330
71. Soutar C.A., Costello J., Ijaduola O., and Turner-Warwick M. Nocturnal and morning asthma. Relationship to plasma corticosteroids and response to cortisol infusion. Thorax 30 (1975) 436-440
72. Soutar C.A., Carruthers M., and Pickering C.A. Nocturnal asthma and urinary adrenaline and nor-adrenaline excretion. Thorax 32 (1977) 77-683
73. Morrison J.F.J., Pearson S.B., and Dean H.G. Parasympathetic nervous system in nocturnal asthma. Br. Med. J. 296 (1988) 1427-1429
74. Sutherland E.R., Ellison M.C., Kraft M., and Martin R.J. Altered pituitary-adrenal interaction in nocturnal asthma. J. Allergy Clin. Immunol. 112 (2003) 52-57
75. Kraft M., Vianna E., Martin R.J., and Leung D.Y. Nocturnal asthma is associated with reduced glucocorticoid receptor binding affinity and decreased steroid responsiveness at night. J. Allergy Clin. Immunol. 103 (1999) 66-71
76. Kraft M., Hamid Q., Chrousos G.P., Martin R.J., and Leung D.Y. Decreased steroid responsiveness at night in nocturnal asthma. Is macrophage responsible?. Am. J. Respir. Crit. Care Med. 163 (2001) 1219-1225
77. Sutherland E.R., Martin R.J., Ellison M.C., and Kraft M. Immunomodulatory effects of melatonin in asthma. Am. J. Respir. Crit. Care Med. 166 (2002) 1055-1061
78. Sutherland E.R., Ellison M.C., Kraft M., and Martin R.J. Elevated serum metabolism is associated with the nocturnal worsening of asthma. J. Allergy Clin. Immunol. 112 (2003) 513-517
79. Martin R.J., Cicutto L.C., and Ballard R.D. Factors related to the nocturnal worsening of asthma. Am. Rev. Respir. Dis. 141 (1990) 33-38
80. Ballard R.D. Effects of sleep on respiratory physiology in nocturnal asthma. In: Martin R.J. (Ed). Nocturnal Asthma: Mechanisms and Treatment (1993), Futura Publ. Co. Mt Kisco, NY 117-161
81. Ballard R.D., Saathoff M.C., Patel D.K., Kelly P.L., and Martin R.J. Effects of sleep on nocturnal bronchoconstriction and ventilatory patterns in asthmatics. J. Appl. Physiol. 67 (1989) 243-249
82. Ballard R.D. Sleep, respiratory physiology, and nocturnal asthma. Chronobiol. Int. 16 (1999) 565-580
83. Chan C.S., Woolcock A.J., and Sullivan C.E. Nocturnal asthma: role of snoring and obstructive sleep apnea. Am. Rev. Respir. Dis. 137 (1988) 1502-1504
84. Martin M.E., Grunstein M.M., and Larsen G.L. The relationship of gastroesophageal reflux to nocturnal wheezing in children with asthma. Ann. Allergy 49 (1982) 318-322
85. Harding S.M. Nocturnal asthma: role of nocturnal gastroeosophageal reflux. Chronobiol. Int. 16 (1999) 641-662
86. Babb R.R., Notarangelo J., and Smith V.M. Wheezing as a clue to gastroesophageal reflux. Am. J. Gastroenterol. 53 (1970) 230-233
87. Goodall R.J.R., Earis J.E., Cooper D.N., Bernstein A., and Temple J.G. Relationship between asthma and gastro-esophageal reflux. Thorax 36 (1981) 116-121
88. Tan W.C., Martin R.J., Pandey R., and Ballard R.D. Effects of spontaneous and stimulated gastroesophageal reflux on sleeping asthmatics. Am. Rev. Respir. Dis. 141 (1990) 1394-1399
89. National Asthma Education and Prevention Program Expert Panel Report. Guidelines for the Diagnosis and Management of Asthma. Update on Selected Topics-2002 [EPR-Update 2002]. NIH Publication vol. 02-5074 (June 2003). http://www.nhlbi.nih.gov/guidelines/asthma/index.htm http://www.nhlbi.nih.gov/guidelines/asthma/index.htm
90. Smolensky M.H., McGovern J.P., Scott P.H., and Reinberg A. Chronobiology and asthma. II. Body-time-dependent differences in the kinetics and effects of bronchodilator medications. J. Asthma 24 (1987) 90-134
91. Smolensky M.H., and D'Alonzo G.E. Progress in the chronotherapy of nocturnal asthma. In: Redfern P.H., and Lemmer B. (Eds). Physiology and Pharmacology of Biological Rhythms. Handbook of Pharmacology vol. 125 (1997), Springer-Verlag, Heidelberg 205-249
92. Lemmer B. Zirkadiane Rhythmik bei Asthma bronchiale. Pneumol. Not. 2 (1995) 18-23
93. Dahl R., Pedersen B., and Venge P. Bronchoalveolar lavage studies. Eur. Respir. Rev. 1 (1991) 272-275
94. Johnson M., Butchers P.R., and Vardey C.J. Potency and duration of action of salmeterol as an inhibitor of mediator release from human lung. Am. Rev. Respir. Dis. 143 (1991) A655 (Abstract)
95. 2-adrenoceptor agonists in allergic inflammation. Clin. Exp. Allergy 22 (1992) 177-181
96. Twentyman O.P., Finnerty J.P., Harris A., Palmer J., and Holgate S.T. Protection against allergen-induced asthma by salmeterol. Lancet 336 (1990) 1338-1342
97. Butchers P.R., Cousins S.A., and Vardey C.J. Salmeterol: a potent and long-acting inhibitor of the release of inflammatory and spasmogenic mediators from human lungs. Br. J. Pharmacol. 92 (1987) 745P (Suppl) (Abstract)
98. Maneechotesuwan K., Essilfie-Quaye S., Meah S., Kelly C., Kharitonov S.A., Adcock I.M., and Barnes P.J. Formoterol attenuates neurophilic airway inflammation in asthma. Chest 128 (2005) 1936-1942
99. Brown A.C., Smolensky M.H., and D'Alonzo G.E. Day-night variation in airways status in sympathomimetic and theophylline-treated asthma patients. J. Osteopath. Med. 93 (1993) 321-333
100. Joad J.P., Ahrens R.C., Lindgren S.D., and Weinberger M.M. Relative efficacy of maintenance therapy with theophylline, inhaled albuterol, and the combination for chronic asthma. J. Allergy Clin. Immunol. 79 (1987) 78-85
101. Zwillich C.W., Neagley S.R., Cicutto L., White D.P., and Martin R.J. Nocturnal asthma therapy: inhaled bitolterol versus sustained-release theophylline. Am. Rev. Respir. Dis. 139 (1989) 470-474
102. Walters E.H., Walters J.A., and Gibson P.W. Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma. Cochrane Database Syst. Rev. (2002) CD003901
103. Kemp J.P., Bierman C.W., and Cocchetto D.M. Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and holter monitoring. Ann. Allergy 70 (1993) 316-322
104. Johnson M. The preclinical pharmacology of salmeterol: bronchodilator effects. Eur. Respir. Rev. 1 (1991) 253-256
105. Barnes P.J., Fitzgerald G.A., and Dollery C.T. Circadian variation in adrenergic response in asthmatic subjects. Clin. Sci. 62 (1982) 349-354
106. Fitzgerald G.A., Barnes P., Brown M.J., and Dollery C.T. The circadian variability of circulating adrenaline and bronchomotor reactivity in asthma. In: Smolensky M.H., Reinberg A., and Labrecque G. (Eds). Recent Advances in the Chronobiology of Allergy and Immunology (1980), Pergamon Press, Oxford 89-94
107. Brown A., Smolensky M., D'Alonzo G.E., Frankoff H., Gianotti L., and Nilsestuen J. Circadian chronesthesy of the airways of healthy adults to the β-agonist bronchodilator isoproterenol. Ann. Rev. Chronopharmacol. 5 (1988) 163-166
108. Gaultier C., Reinberg A., and Girard F. Circadian changes in lung resistance and dynamic compliance in healthy and asthmatic children. Effects of two bronchodilators. Respir. Physiol. 31 (1975) 169-182
109. Gaultier C., Reinberg A., and Motohashi Y. Circadian rhythm in total pulmonary resistance of asthmatic children. Effects of a β-agonist agent. Chronobiol. Int. 5 (1988) 285-290
110. Bogin R.M., and Ballard R.D. Treatment of nocturnal asthma with pulse-release albuterol. Chest 102 (1992) 362-366
111. Eriksson N.E., Haglind K., and Ljungholm K. A comparison of sustained-release terbutaline and ordinary terbutaline in bronchial asthma. Br. J. Dis. Chest 76 (1982) 202-204
112. Eriksson L., Jonson B., Eklundh G., and Persson G. Nocturnal asthma: effects of slow-release terbutaline on spirometry and arterial blood gases. Eur. Respir. J. 1 (1988) 302-305
113. Grossman J., Morris R.J., White K.D., and Cocchetto M. Improved stability in oral delivery of albuterol provides less variability in bronchodilation in adults with asthma. Ann. Allergy 66 (1991) 324-327
114. Maesen F.P.V., and Smeets J.J. Comparison of a controlled-release tablet of salbutamol given twice daily with a standard tablet given four times daily in the management of chronic obstructive lung disease. Eur. Respir. J. 31 (1986) 431-436
115. Postma D.S., Koeter G.H., Mark T.W.v.d., Reig R.P., and Sluiter H.J. The effects of oral slow-release terbutaline on the circadian variation in spirometry and arterial blood gas levels in patients with chronic airflow obstruction. Chest 87 (1985) 653-657
116. Postma D.S., Koeter G.H., Keyzer J.J., and Meurs H. Influence of slow-release terbutaline on the circadian variation of catecholamines, histamine, and lung function in nonallergic patients with partly reversible airflow obstruction. J. Allergy Clin. Immunol. 77 (1986) 471-477
117. Koeter G.H., Postma D.S., Keyzer J.J., and Meurs H. Effect of oral slow-release terbutaline on early morning dyspnea. Eur. J. Clin. Pharmacol. 28 (1985) 159-162
118. Dahl R., Harving H., Sawedal L., and Anchus S. Terbutaline sustained-release tablets in nocturnal asthma - a placebo-controlled comparison between a high and low evening dose. Br. J. Dis. Chest 82 (1988) 237-241
119. Bollinger A.M., Young K.Y.L., Gambertoglio J.G., Newth C.J.L., Zureikat G., Powell M., Leung P., Affirme M.B., Symchowicz S., and Patrick J.E. Influence of food on the absorption of albuterol Repatabs. J. Allergy Clin. Immunol. 83 (1989) 123-126
120. Hussey E.K., Donn K.H., and Powell J.R. Albuterol extended-release products: a comparison of steady-state pharmacokinetics. Pharmacotherapy 11 (1991) 131-135
121. Powell M.L., Weisberger M., Dowdy Y., Gural R., Symchowicz S., and Patrick J.E. Comparative steady-state bioavailability of conventional and controlled-release formulations of albuterol. Biopharm. Drug Dispos. 8 (1987) 461-467
122. Storms W.W., Nathan R.A., Bodman S.F., Morris R.J., Selner J.C., Greenstein S.M., and Zwillich C.W. The effect of repeat action albuterol sulfate (Proventil Repetabs) in nocturnal symptoms of asthma. J. Asthma 29 (1992) 209-216
123. Grossman J., Morris R.J., White K.D., and Cocchetto M. Improved stability in oral delivery of albuterol provides less variability in bronchodilation in adults with asthma. Ann. Allergy 66 (1991) 324-327
124. Higenbottam M.A., Khan A., Williams D.O., Mikhail J.R., Peake M.D., and Hughes L. Controlled release Salbutamol tablets verses aminophylline in the control of reversible airways obstruction. J. Int. Med. Res. 17 (1989) 435-441
125. Pierson W.E., LaForce C.F., Bell T.D., MacCosbe P.E., Sykes R.S., and Tinkelman D. Long-term, double-blind comparison of controlled-release albuterol versus sustained-release theophylline in adolescents and adults with asthma. J. Allergy Clin. Immunol. 85 (1990) 618-626
126. Sykes R.S., Reese M.E., Meyer M.C., and Chubb J.M. Relative bioavailability of a controlled-release albuterol formulation for twice-daily use. Biopharm. Drug Dispos. 9 (1988) 551-556
127. Creemers J.D. A multicenter comparative study of salbuterol controlled release (Volmax) and sustained-release theophylline (Theo-Dur) in the control of nocturnal asthma. Eur. Respir. J. 1 Suppl 2 (1988) 333s (Abstract)
128. Moore-Gillon J. Volmax (salbutamol CR 8 mg) in the management of nocturnal asthma: a placebo-controlled study. Eur. Respir. J. 1 Suppl 2 (1988) 306s (Abstract)
129. Pedersen B.K., Laursen L.C., Gnosspelius Y., Faurschou P., and Weeks B. Bambuterol: effects of a new anti-asthmatic drug. Eur. J. Clin. Pharmacol. 29 (1985) 425-427
130. Persson G., Gnosspelius Y., and Anehus S. Comparison between a new once-daily, bronchodilating drug, bambuterol, and terbutaline sustained-release, twice-daily. Eur. Respir. J. 1 (1988) 223-226
131. D'Alonzo G.E., Smolensky M.H., Feldman S., Gnosspelius Y., and Karlsson K. Bambuterol in the treatment of asthma. A placebo-controlled comparison of once-daily morning vs. evening administration. Chest 107 (1995) 406-412
132. Arvidsson P., Larsson S., Lofdahl C.G., Melander B., Svedmyr N., and Wahlander L. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur. Respir. J. 4 (1991) 1168-1173
133. Kesten S., Chapman K.R., Broder I., Cartier A., and Hyland R.H. Sustained improvement in asthma with long-term use of formoterol fumarate. Ann. Allergy 69 (1992) 415-420
134. 2-adrenergic agonist: characterization of pharmacological activity in vitro and in vivo. Br. J. Pharmacol. 104 (1991) 665-671
135. Derom E., Pauwels R., and Van Der Straeten M. Duration of the protective effect of salmeterol on methacholine challenge of asthmatics. Am. Rev. Respir. Dis. 141 (1990) A469 (Suppl) (Abstract)
136. Maconochie J.G., Forster J.K., Fowler P., and Thomas M. An initial comparison of salmeterol and salbutamol against histamine-induced bronchoconstriction in healthy subjects. Br. J. Clin. Pharmacol. 25 (1988) 115P (Abstract)
137. 2-adrenergic agonist, has longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. J. Allergy Clin. Immunol. 89 (1992) 567-574
138. Persson C.G.A. Role of plasma exudation in asthmatic airways. Lancet ii (1986) 1126-1128
139. Finnerty J.P., Twentyman O.P., and Holgate S.T. The duration of action of salmeterol as a bronchodilator and functional antagonist of histamine-induced bronchoconstriction. Am. Rev. Respir. Dis. 143 4pt2 (1991) A654 (Abstract)
140. Pedersen B., and Dahl R. The effect of salmeterol on the early and late reaction to bronchial allergen challenge and hyperreactivity in patients with bronchial asthma. Clin. Exp. Allergy 20 Suppl 1 (1990) 94 (Abstract)
141. Pedersen B., Dahl R., and Venge P. The effect of salmeterol on the early and late phase reaction to bronchial allergen challenge and postchallenge variation in bronchial hyperreactivity, blood eosinophils and serum eosinophil cationic protein. Am. Rev. Respir. Dis. 143 4pt2 (1991) A649 (Abstract)
142. Pedersen B., Dahl R., Larsen B.B., and Venge P. The effect of salmeterol on the early- and late-phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X. Allergy 48 (1993) 377-382
143. Brambilla C., Chastang C., Georges D., and Bertin L. Salmeterol compared with slow-release terbutaline in nocturnal asthma. Allergy 49 (1994) 421-426
144. Britton M.G., Earnshaw J.S., and Palmer J.B.D. A twelve month comparison of salmeterol and salbutamol in asthmatic patients. Eur. Respir. J. 5 (1992) 1062-1067
145. D'Alonzo G.E., Nathan R.A., Henochowicz S., Morris R.J., Rathner P., and Rennard S.I. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 271 (1994) 1412-1416
146. 2 agonist. Br. Med. J. 301 (1990) 1365-1368
147. Lundback B., Rawlinson D.W., and Palmer J.B.D. Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. Thorax 48 (1993) 148-153
148. Pearlman D.S., Chervinsky P., LaForce C., Seltzer J.M., Southern D.L., Kemp J.P., Dockhorn R.J., Grossman J., Liddle R.F., Yancey S.W., Cocchetto D.M., Alexander W.J., and van As A. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N. Engl. J. Med. 327 (1992) 1420-1425
149. Ullman A., Hedner J., and Svedmyr N. Inhaled salmeterol and salbutamol in asthmatic patients. Am. Rev. Respir. Dis. 142 (1990) 571-575
150. Faurschou P., Engel A.-M., and Haanaes O.C. Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies. Allergy 49 (1994) 827-832
151. Horiguchi T., Kondo R., Miyazaki J., Fukumokto K., and Torigoe H. Clinical evaluation of a transdermal therapeutic system of the beta2-agonist tulobuterol in patients with mild or moderate persistent bronchial asthma. Arzneimittelforsch 54 (2004) 280-285
152. Burioka N., Miyata M., Endo M., Fukuoka Y., Suyama H., Nakazaki H., Igawa K., and Shimizu E. Alteration of the circadian rhythm in peak expiratory flow of nocturnal asthma following nighttime transdermal beta2-adrenoceptor agonist tulobuterol chronotherapy. Chronobiol. Int. 22 (2005) 383-390
153. Coe C.I., and Barnes P.J. Reduction of nocturnal asthma by an inhaled anticholinergic drug. Chest 90 (1986) 485-488
154. Cox I.D., Hughes D.T.D., and McConnell K. Ipratropium bromide in patients with nocturnal asthma. Postgrad. Med. J. 60 (1984) 526-528
155. Catterall J.L., Rhind G.B., Whyte K.F., Shapiro C.M., and Douglas N.J. Is nocturnal asthma caused by changes in airway cholinergic activity?. Thorax 43 (1988) 720-724
156. Morrison J.F.J., Pearson S.B., and Dean H.G. Parasympathetic nervous system in nocturnal asthma. Br. Med. J. 296 (1988) 1427-1429
157. Sly P.D., Landau L.I., and Olinsky A. Failure of ipratropium bromide to modify the diurnal variation of asthma in asthmatic children. Thorax 42 (1987) 357-360
158. Wolstenholme R.J., and Shettan S.P. Comparison of a combination of fermoterol with ipratropium bromide (Duovent) and salbutamol in young adults with nocturnal asthma. Respiration 55 (1989) 152-157
159. O'Conner B.J., Towse L.J., and Barnes P.J. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am. J. Respir. Crit. Care Med. 154 (1996) 876-880
160. Disse B., Speck G.A., Rominger K.L., Witek T.J., and Hammer R. Tiotropium (Spiriva®): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 64 (1999) 457-464
161. Calverley P.M., Lee A., Towse L., van Noord J., Witek T.J., and Kelsen S. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 58 (2003) 855-860
162. Kidney J.C., Dominguez M., Taylor P.M., Rose M., Chung K.F., and Barnes P.J. Immunomodulation by theophylline in asthma. Demonstration by withdrawing of therapy. Am. J. Respir. Care Med. 151 (1995) 1907-1914
163. Pauwels R., Van Renerghem D., Van Der Straeten M., Johannesson N., and Persson C.G.A. The effect of theophylline and emprofylline on allergen induced-bronchoconstriction. J. Allergy Clin. Immunol. 76 (1985) 583-590
164. Sullivan P., Songul B., Jaffar Z., Page C., Jeffery P., and Costello J. Anti-inflammatory effects of low dose oral theophylline in atopic asthma. Lancet 343 (1994) 1006-1008
165. Ward A.J.M., McKenniff M., Evans J.M., Page C.P., and Costello J.F. Theophylline-an immunomodulatory role in asthma?. Am. Rev. Respir. Dis. 147 (1993) 518-523
166. Smolensky M.H. Chronopharmacology of theophylline and beta-sympathomimetics. In: Lemmer B. (Ed). Cellular and Biochemical Aspects of Chronopharmacology (1989), Marcel Dekker, Inc., New York 65-113
167. D'Alonzo Jr. G.E., Crocetti J.G., and Smolensky M.H. Circadian rhythms in the pharmacokinetics and clinical effects of beta-agonist, theophylline, and anticholinergic medications in the treatment of nocturnal asthma. Chronobiol. Int. 16 (1999) 663-682
168. Smolensky M.H., Scott P.H., Harrist R., Hiat H., Wong T., Baenziger J.C., Klank B., Marbella A., and Meltzer A. Administration-time-dependency of pharmacokinetic behavior and therapeutic effect of a once-a-day theophylline in asthmatic children. Chronobiol. Int. 4 (1987) 435-447
169. Reinberg A., Smolensky M.H., Labrecque G., and Hallek M. Aspects of chronopharmacology and chronotherapy in children. Chronobiologia 14 (1987) 303-325
170. Goo R.H., Moore J.G., Greenberg E., and Alazraki N.P. Circadian variation in gastric emptying of meals in man. Gastroenterology 93 (1987) 515-518
171. Moore J.G., and Englert E. Circadian rhythm of gastric acid secretion in man. Nature 226 (1970) 1261-1262
172. Reinberg A., Labrecque G., and Smolensky M.H. Chronobiologie et Chronotherapeutique. Heure optimale d'administration des medicaments, Medecine-Sciences (1991), Flammarion, Paris 298 pp.
173. Vener K.J., and Moore J.G. Chronobiologic properties of the alimentary canal affecting xenobiotic absorption. Ann. Rev. Chronopharmacol. 4 (1988) 259-283
174. Lemmer B., and Labrecque G. Chronopharmacology and chronotherapeutics:
175. Bruguerolle B., and Lemmer B. Recent advances in chronopharmacokinetics: methological problems. Life Sci. 52 (1993) 1809-1824
176. Bélanger P.M., Bruguerolle B., and Labrecque G. Rhythms in pharmacokinetics; Absorption, distribution, metabolism and excretion. In: Redfern P.H., and Lemmer B. (Eds). In Physiology and Pharmacology of Biological Rhythms. Handbook of Pharmacology vol. 125 (1997), Springer-Verlag, Heidelberg 177-204
177. Smolensky M.H., Scott P.H., Albright D., and McGovern J.P. Circadian difference in theophylline effect during constant-rate infusion with aminophylline. Ann. Rev. Chronopharmacol. 3 (1986) 139-142
178. Warren J.B., Cuss F., and Barnes P.J. Posture and theophylline kinetics. Br. J. Clin. Pharmacol. 19 (1985) 707-709
179. Kyle G.M., Smolensky M.H., and McGovern J.P. Circadian variation in the susceptibility of rodents to the toxic effects of theophylline. In: Reinberg A., and Halberg F. (Eds). Chronopharmacology (1979), Pergamon Press, Oxford 239-244
180. D'Alonzo G.E., Smolensky M.H., Feldman S., Gianotti L.A., Emerson M.B., Staudinger H., and Steinijans V.M. Twenty-four-hour lung function in adult patients with asthma: chronoptimized theophylline therapy once-daily dosing in the evening versus conventional twice-daily dosing. Am. Rev. Respir. Dis. 142 (1990) 84-90
181. Darow P., and Steinijans V.W. Therapeutic advantage of unequal dosing of theophylline in patients with nocturnal asthma. Chronobiol. Int. 4 (1987) 349-357
182. Philip-Joet F., Bruguerolle B., Parrel M., Vestri R., and Arnaud A. Time-related distribution of delayed-action theophylline in the treatment of chronic obstructive bronchopneumopathies. Presse Med. 17 (1988) 193-196
183. Wang P., Qi M., Zhong D., and Fang L. Pharmacokinetics of a new sustained-release formulation of theophylline sodium glycerinate in healthy subjects with a new asymmetric dosage regimen. Biomed. Chromatogr. 17 (2003) 58-61
184. Germouty J., Bida C., and Moreau L. Prescription of Theostat 300 as a single evening dose. Rev. Pneumol. Clin. 43 (1987) 262-265
185. Frankoff H.M., Smolensky M.H., D'Alonzo G.E., Gianotti L., Hsi B., and McGovern J.P. Comparison of sustained-release theophylline scheduled conventionally (twice-daily, equal interval in equal amount) versus once-daily mornings or evenings on circadian pattern of bronchial patency in adult asthmatics. Chronobiol. Int. 4 (1987) 421-433
186. Goldenheim P.D., Conrad E.A., and Schein L.K. Treatment of asthma by a controlled-release theophylline tablet formulation: a review of the North American experience with nocturnal dosing. Chronobiol. Int. 4 (1987) 397-408
187. Martin R.J., Cicutto L.C., Ballard R.D., Goldenheim P.D., and Cherniack R.M. Circadian variations in theophylline concentrations and the treatment of nocturnal asthma. Am. Rev. Respir. Dis. 139 (1989) 475-478
188. Neuenkirchen H., Wikens J.H., Oellerich M., and Sybrecht G.W. Nocturnal asthma: effect of a once per evening dose of sustained-release theophylline. Eur. J. Respir. Dis. 66 (1985) 196-204
189. Reinberg A., Pauchet F., Ruff F., Gervais A., Smolensky M.H., Lévi F., Gervais P., Chaouat D., Abella M.L., and Zidani R. Comparison of once-daily evening versus morning sustained-release theophylline dosing for nocturnal asthma. Chronobiol. Int. 4 (1987) 409-420
190. Steinijans V.W., Schulz H.-U., Beier W., and Radtke H.W. Once daily theophylline: multiple-dose comparison of an encapsulated micro-osmotic system (Euphylong) with a tablet (Uniphyllin). Int. J. Clin. Pharmacol. 24 (1986) 43-47
191. Kraft M., Torvik J.A., Trudeau J., Wenzel S.E., and Martin R.J. Theophylline potential anti-inflammatory effects in nocturnal asthma. J. Allergy Clin. Immunol. 97 (1996) 1242-1246
192. Barnes P.J. Effect of corticosteroids on airway hyperresponsiveness. Am. Rev. Respir. Dis. 141 (1990) S70-S76
193. Barnes P.J. Inhaled glucocorticoids for asthma. N. Eng. J. Med. 332 (1995) 868-875
194. Leung S.Y., Eynott P., Nath P., and Chung K.F. Effects of ciclesonide and fluticasone propionate on allergen-induced airway inflammation and remodeling features. J. Clin. Allergy Immunol. 115 (2005) 989-996
195. English J., and Marks V. Diurnal variations in methylprednisolone metabolism in the rat. IRCS Med. Sci. 9 (1981) 721
196. English J., Dunne M., and Marks V. Diurnal variation in prednisone kinetics. Clin. Pharmacol. Ther. 33 (1983) 381-385
197. McAllister W.A.C., Mitchell D.M., and Collins J.V. Prednisolone pharmacokinetics compared between night and day in asthmatic and normal subjects. Br. J. Clin. Pharmacol. 11 (1981) 303-304
198. Morselli P.L., Marc V., Garattini S., and Zaccala M. Metabolism of exogenous cortisol in humans-diurnal variations in plasma disappearance rate. Biochem. Pharmacol. 19 (1970) 1643-1647
199. DiRaimondo V.C., and Forsham P.H. Some clinical implications of the spontaneous diurnal variation in adrenal cortical secretory activity. Am. J. Med. 21 (1956) 231
200. Reinberg A., Halberg F., and Falliers C. Circadian timing of methylprednisolone effects in asthmatic boys. Chronobiologia 1 (1974) 333-347
201. Ceresa F., Angeli A., Buccuzzi G., and Molino G. Once-a-day neurally stimulated and basal ACTH secretion phases in man and their response to corticoid inhibition. J. Clin. Endocrinol. 29 (1969) 1074-1082
202. Angeli A. Circadian ACTH-adrenal rhythm in man. Chronobiologia 1 Suppl. 1 (1974) 253-268
203. Nichols T., Nugent C.A., and Tyler F.H. Diurnal variations in suppression of adrenal function by glucocorticoids. J. Clin. Endocrinol. Metabol. 25 (1965) 343-349
204. Grant S.D., Forsham P.H., and DiRaimando V.C. Suppression of 17-hydroxycorticosteroids in plasma and urine after single and divided doses of triamcinolone. N. Engl. J. Med. 273 (1965) 1115-1118
205. Reinberg A., Smolensky M.H., D'Alonzo G.E., and McGovern J.P. Chronobiology of asthma. III: timing corticotherapy to biological rhythms to optimize treatment goals. J. Asthma 25 (1988) 219-248
206. Reinberg A.E. Chronopharmacology of corticosteroids and ACTH. In: Lemmer B.J. (Ed). Chronopharmacology: Cellular and Biochemical Interactions (1989), Marcel Dekker, New York 137-167
207. Beam W.R., Weiner D.E., and Martin R.J. Timing of prednisone and alteration of airways inflammation in nocturnal asthma. Am. Rev. Respir. Dis. 146 (1992) 1524-1530
208. Harter J.G., Reddy W.J., and Thorn G.W. Studies on an intermittent corticosteroid dosage regimen. N. Engl. J. Med. 296 (1963) 591-595
209. Reinberg A., Guillet P., Gervais P., Ghata J., Vignaud D., and Abulker C. One-month chronocorticotherapy (Dutimelan 8-15 mite): control of the asthma condition without adrenal suppression and circadian alteration. Chronobiologia 4 (1977) 295-312
210. Reinberg A., Gervais P., Chaussade M., Fraboulet G., and Duburque B. Circadian changes in the effectiveness of corticosteroids in eight patients with allergic asthma. J. Allergy Clin. Immunol. 71 (1983) 425-433
211. Reindl K., Falliers C., Halberg F., Chai H., Hillman D., and Nelson W. Circadian acrophase in peak expiratory flow and urinary electrolyte excretion of asthmatic children; phase shifting of rhythms by prednisone given at different circadian system phases. Rass. Neurol. Veg. 23 (1969) 5-26
212. Kowanko I., Readett R., Pownall R., Swannell A.J., Mahoney P., and Knapp M.S. Nocturia, a side effect of single dose prednisolone and its dependence on time of day of taking steroid. In: Reinberg A., and Halberg F. (Eds). Chronopharmacology (1978), Pergamon Press, Oxford 63
213. Reinberg A., Ghata J., Halberg F., Apfelbaum M., Gervais P., Boudon P., Abulker C., and Dupont J. Distribution temporelle du traitment de l'insuffisance corticosurrénalienne. Essai chronotherapeutique. Ann. Endocrinol. 32 (1971) 566-573
214. Reinberg A., Ghata J., and Abulker C. Chronic (5 to 24 years) chronocorticotherapy in adrenocortical insufficiency. Comparison between two treatment schedules. In: Reinberg A., and Halberg F. (Eds). Chronopharmacology (1974), Pergamon Press, Oxford 77-84
215. Lemmer B. Bronchospamolytika und Antiasthmatika. In: Schwabe U., and Paffrath D. (Eds). Arzneiverordnunbgs-Report 2005 (2005), Springer, Heidelberg 515-522
216. Peterson L. Trends-in-Medicine (2002) 5-6. http://www.trends http://www.trends-in-medicine.com/Sept2002/EuroResp092p.pdf
217. Dyer M.J., Halpin D.M., and Stein K. Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone versus inhaled fluticasone for chronic asthma in adults: a systematic review. BMC Fam. Pract. 7 (2006) 34
218. Lipworth B.J., and Jackson C.M. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Safety 23 (2000) 11-33
219. Derendorf H., Hübner M., Drewelow B., Fuhr U., Gleiter C.H., Lemmer B., Mikus G., Roots I., Ziegler A., and Ukena D. Ciclesonid - Pharmakokinetische und pharmakodynamische Eigenschaften. Arzneimitteltherapie 25 (2007) 89-94
220. Holliday S.M., Faulds D., and Sorkin E.M. Inhaled fluticasone propionate: a review of its pharmacodynamics and pharmacokinetic properties, and therapeutic use in asthma. Drugs 47 (1994) 319-331
221. Chaplin M.D., II Rooks W., Swenson E.W., Cooper W.C., Nerenberg C., and Chu N.I. Flunisolide metabolism and dynamics of a metabolite. Clin. Pharmacol. Ther. 27 (1980) 402-413
222. Ryrfeldt A., Andersson P., Edsbacker S., Tonnesson M., Davies D., and Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur. J. Respir. Dis. 63 (1982) 86-95 (Suppl.)
223. Smolensky M.H., and D'Alonzo G.E. Medical chronobiology: concepts and applications. Am. Rev. Respir. Dis. 147 (1993) 511-519
224. Wilson A.M., and Lipworth B.J. 24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids. Thorax 54 (1999) 20-26
225. Toogood J.H., Baskerville J.C., Jennings B., Lefco N.M., and Johansson S.A. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J. Allergy Clin. Immunol. 70 (1982) 288-298
226. Pincus D.J., Szefler S.J., Ackerson L.M., and Martin R.J. Chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J. Allergy Clin. Immunol. 95 (1995) 1172-1178
227. Pincus D.J., Humeston T.R., and Martin R.J. Further studies on the chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J. Allergy Clin. Immunol. 100 (1997) 771-774
228. Kemp J.P., Berkowitz R.B., Miller S.D., Murry J.J., Nolop K., and Harrison J.E. Mometasone furoate administration once daily is as effective as twice daily administration for treatment of mild-to-moderate persistent asthma. J. Allergy Clin. Immunol. 106 (2000) 485-492
229. Bensch G.W., Prenner B., Berkowitz R., Galant S., Ramsdell J., and Lutsky B. Once-daily evening administration of mometasone furoate in asthma treatment initiation. Ann. Allergy, Asthma, & Immunol. 96 (2006) 533-540
230. Karpel J.P., Busse W.W., Noonan M.J., Monahan M.E., Lutsky B., and Staudinger H. Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. Ann. Pharmacother. 39 (2005) 1977-1983
231. Karpel J.P., Busse W.W., Boulet L.P., Monahan M.E., Lutzky B., and Staudinger H. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Curr. Med. Res. Opin. 21 (2005) 1281-1289
232. Noonan M., Karpel J.P., Bensch G.W., Ramsdell J.W., Webb D.R., Nolop K.B., and Lurtsky B.N. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann. Allergy, Asthma, & Immunol. 86 (2001) 36-43
233. D'Urzo A., Karpel J.P., Busse W.W., Boulet L.P., Monahan M.E., Lutzky B., and Staudinger H. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Curr. Med. Res. Opin. 21 (2005) 1281-1289
234. ZuWallack R.L., Rosen J.P., Cohen L., Rachelefsky G.S., Gong H., Goldsobel A.B., Kaliner M.A., White M.V., Bronsky E.A., Chervinsky P., Lotner G.Z., Corren J., and Bodenheimer S. The effectiveness of once-daily dosing of inhaled flunisolide in maintaining asthma control. J. Allergy Clin. Immunol. 99 (1997) 278-285
235. Christie P. Ciclesonide: a novel inhaled corticosteroid for asthma. Drugs Today (Barc) 40 (2004) 569-576
236. Leach C.L., Bethke T.D., Boudreau R.J., Hasseiquist B.E., Drollmann A., Davidson P., and Wurst W. Two-dimensional and three dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers. J. Aerosol Med. 19 (2006) 117-126
237. Pearlman D.S., Berger W.E., Kerwin E., Laforce C., Kundu S., and Banerji D. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J. Allergy Clin. Immunol. 116 (2005) 1206-1212
238. Langon C.G., Adler M., Mehra S., Alexander M., and Drollmann A. Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma. Respir. Med. 99 (2005) 1275-1285
239. Chapman K.R., Patel P., D'Urzo A.D., Alexander M., Mehra S., Oedekoven C., Engelstätter R., and Boulet L.P. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 60 (2005) 330-337
240. Lipworth B.J., Kaliner M.A., LaForce C.F., Baker J.W., Kaiser H.B., Amin D., Kundu S., Williams J.E., Engelstätter R., and Banerji D.D. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann. Allergy, Asthma, & Immunol. 94 (2005) 465-472
241. Szefler S., Rohatagi S., Williams J., Lloyd M., Kundu S., and Banerji D. Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest 128 (2005) 1104-1114
242. Weinbrenner A., Hüneke D., Zschiesche M., Engel G., Timmer W., Steinijans V.W., Bethke T., Wurst W., Drollmann A., Kaatz H.J., and Siegmund W. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J. Clin. Endocrinol. Metab. 87 (2002) 2160-2163
243. Postma D.S., Sevette C., Martinat Y., Schlosser N., Aumann J., and Kafe J. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur. Respir. J. 17 (2001) 1083-1088
244. Gauvreau G.M., Boulet L.P., Postma D.S., Kawayama T., Watson R.M., Duong M., Deschesnes F., DeMonchy J.G., and O'Byrne P.M. Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma. J. Allergy Clin. Immunol. 116 (2005) 285-291
245. Buhl R., Vinkler I., Maygar P., Gyori Z., Rybacki C., Middle M.V., Escher A., and Engelstatter R. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulm. Pharmacol. Ther. 19 (2005) 404-412
246. Kraft M. Corticosteroids and leukotrienes: chronobiology and chronotherapy. Chronobiol. Int. 16 (1999) 683-693
247. Wenzel S.E., Trudeau J.B., and Kaminsky D.A. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airways inflammation in nocturnal asthma. Am. J. Respir. Crit. Care Med. 152 (1995) 897-905
248. Vianna E.O., and Martin R.J. Recent innovations in asthma therapy. Drugs Today (Barc) 34 (1998) 341-351
249. Kemp J.P. Recent advances in the management of asthma using leukotriene modifiers. Am. J. Respir. Med. 2 (2003) 139-156
250. Drazen J.M., Israel E., and O'Byrne P.M. Treatment of asthma with drugs modifying the leukotrien pathway. N. Engl. J. Med. 340 (1999) 197-206
251. Ducharme F.M. Inhaled glucocorticoids versus leukotrien receptor antagonists as single agent asthma treatment: systematic review of current evidence. Br. Med. J. 326 (2003) 619-624
252. Reiss T.F., Chervinsky P., Dockhorn R.J., Shingo S., Seidenberg B., and Edwards T.B. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial, Montelukast Clinical Research Study. Arch. Intern. Med. 158 (1998) 1213-1220
253. Noonan M.J., Chervinsky P., Brandon M., Zhang J., Kundu S., McBurney J., and Reiss T.F. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur. Respir. J. 11 (1998) 1232-1239
254. Altman L.C., Munk Z., Seltzer J., Noonan N., Shingo S., Zhang J., and Reiss T.F. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J. Allergy Clin. Immunol. 102 (1998) 50-56
255. Pajaron-Fernandez M., Garcia-Rubia S., Sanchez-Solis M., and Garcia-Marcos L. Montelukast administered in the morning or evening to prevent exercise-induced bronchoconstriction in children. Pediatr. Pulmonol. 41 (2006) 222-227
256. Furukawa C.T., Shapiro G.G., Bierman C.W., Kraemer M.J., Ward D.J., and Pierson W.E. A double-blind study comparing the effectiveness of cromolyn sodium and sustained-release theophylline in childhood asthma. Pediatrics 74 (1984) 453-459
257. Kay A.M. The mode of action of anti-allergic drugs. Ann. Allergy 17 (1987) 154-164
258. Gonzalez P.J., and Brogden R.H. Nedocromil sodium: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of reversible airways disease. Drugs 34 (1987) 560-577
259. Hetzel M.R., Clarke J.H., Gilliam S.J., Isaac P., and Perkins M. Is sodium cromoglycate effective in nocturnal asthma?. Thorax 40 (1985) 793-794
260. Morgan A.D., Connaughton J.J., Caterall J.R., Shapiro C.M., Douglas N.J., and Flenley D.C. Sodium cromoglycate in nocturnal asthma. Thorax 41 (1986) 39-41
261. Williams A.J., and Stableforth D. The addition of nedocromil sodium to maintenance therapy in the management of patients with bronchial asthma. Eur. J. Respir. Dis. 147 (1986) 340-343
262. Fischer F., Rothenberg L., and deCastro M. Equity and working time: A challenge to achieve. Chronobiol. Int. 21 (2005) 813-829
263. Kerkhof G.A., Jansen B., and van Amelsvoort L.G.P.M. Vital working hour schemes: the dynamic balance between various interests. Chronobiol. Int. 23 (2004) 1099-1104
264. Knauth P., Jung D., Bopp W., Gauderer P.C., and Gissel A. Compensation for unfavorable characteristics of irregular individual shift rotas. Chronobiol. Int. 23 (2006) 1277-1284
265. Reinberg A.E., and Smolensky M.H. Night and shift work and transmeridian and space flight. In: Touitou Y., and Haus E. (Eds). Biologic Rhythms in Clinical and Laboratory Medicine (1992), Springer-Verlag, Berlin 243-255
266. Reinberg A.E., Ashkenazi I., and Smolensky M.H. Euchronism, allochronism, and dyschronism: Is internal desynchronization of human circadian rhythms a sign of illness. Chronobiol. Int. 24 (2007) 553-588